Samantha Semenkow
Stock Analyst at Citigroup
(1.99)
# 3,061
Out of 5,081 analysts
61
Total ratings
42%
Success rate
-7.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Initiates: Buy | $102 | $57.13 | +78.54% | 1 | Nov 26, 2025 | |
| AGIO Agios Pharmaceuticals | Initiates: Buy | $38 | $27.49 | +38.23% | 1 | Nov 26, 2025 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Buy | $136 | $104.63 | +29.98% | 1 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,041 → $1,124 | $921.80 | +21.94% | 7 | Nov 17, 2025 | |
| BHVN Biohaven | Maintains: Buy | $28 → $14 | $9.12 | +53.51% | 2 | Nov 13, 2025 | |
| PRME Prime Medicine | Maintains: Neutral | $5 → $4.25 | $3.61 | +17.73% | 5 | Nov 11, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $25 → $26 | $20.70 | +25.60% | 3 | Nov 11, 2025 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Buy | $31 → $33 | $23.10 | +42.86% | 3 | Nov 7, 2025 | |
| BIOA BioAge Labs | Maintains: Buy | $10 → $15 | $9.22 | +62.69% | 5 | Oct 29, 2025 | |
| MLTX MoonLake Immunotherapeutics | Downgrades: Sell | $5 | $13.35 | -62.55% | 3 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $2.50 | +300.00% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $7.14 | +124.09% | 1 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.52 | +163.16% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $31.62 | +89.75% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.23 | +183.69% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $15 | $4.47 | +235.57% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $80 | $8.70 | +819.54% | 2 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $14 | $3.47 | +303.46% | 6 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $2.37 | +534.25% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $22.71 | +120.17% | 3 | Sep 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $26.74 | +109.42% | 3 | Aug 9, 2023 |
Nektar Therapeutics
Nov 26, 2025
Initiates: Buy
Price Target: $102
Current: $57.13
Upside: +78.54%
Agios Pharmaceuticals
Nov 26, 2025
Initiates: Buy
Price Target: $38
Current: $27.49
Upside: +38.23%
Rhythm Pharmaceuticals
Nov 25, 2025
Initiates: Buy
Price Target: $136
Current: $104.63
Upside: +29.98%
argenx SE
Nov 17, 2025
Maintains: Buy
Price Target: $1,041 → $1,124
Current: $921.80
Upside: +21.94%
Biohaven
Nov 13, 2025
Maintains: Buy
Price Target: $28 → $14
Current: $9.12
Upside: +53.51%
Prime Medicine
Nov 11, 2025
Maintains: Neutral
Price Target: $5 → $4.25
Current: $3.61
Upside: +17.73%
Roivant Sciences
Nov 11, 2025
Maintains: Buy
Price Target: $25 → $26
Current: $20.70
Upside: +25.60%
Catalyst Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $31 → $33
Current: $23.10
Upside: +42.86%
BioAge Labs
Oct 29, 2025
Maintains: Buy
Price Target: $10 → $15
Current: $9.22
Upside: +62.69%
MoonLake Immunotherapeutics
Oct 29, 2025
Downgrades: Sell
Price Target: $5
Current: $13.35
Upside: -62.55%
Aug 14, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $2.50
Upside: +300.00%
Jul 16, 2025
Initiates: Buy
Price Target: $16
Current: $7.14
Upside: +124.09%
May 15, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $1.52
Upside: +163.16%
May 2, 2025
Initiates: Buy
Price Target: $60
Current: $31.62
Upside: +89.75%
Dec 2, 2024
Initiates: Buy
Price Target: $12
Current: $4.23
Upside: +183.69%
Aug 9, 2024
Maintains: Buy
Price Target: $8 → $15
Current: $4.47
Upside: +235.57%
Jun 3, 2024
Reinstates: Buy
Price Target: $80
Current: $8.70
Upside: +819.54%
May 22, 2024
Maintains: Buy
Price Target: $10 → $14
Current: $3.47
Upside: +303.46%
May 9, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.37
Upside: +534.25%
Sep 27, 2023
Maintains: Buy
Price Target: $33 → $50
Current: $22.71
Upside: +120.17%
Aug 9, 2023
Maintains: Buy
Price Target: $60 → $56
Current: $26.74
Upside: +109.42%